Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohn's Disease Refractory to Anti-TFNa: UNITI-1.

Sandborn W, Gasink C, Blank M, Lang Y, Johanns J, Gao LL, Sands B, Hanauer S, Feagan B, Targan S, Ghosh S, de Villiers W, Colombel JF, Lee S, Desreumaux P, Loftus E, Vermeire S, Rutgeerts P. O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohn's Disease Refractory to Anti-TFNa: UNITI-1. Inflamm Bowel Dis. 2016 Mar; 22 Suppl 1:S1.

View in: PubMed

collapse authors with profiles